Continuum Advisory’s GSK GSK Stock Holding History

Continuum Advisory’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Buy	+5,000	New	+$264K	0.02%	404
2025 Q4	–	Sell	-5,671	Closed	-$245K	–	463
2025 Q3	$245K	Sell	5,671 -1,285	-18%	-$50.2K	0.03%	391
2025 Q2	$267K	Sell	6,956 -4,973	-42%	-$190K	0.03%	359
2025 Q1	$462K	Sell	11,929 -151	-1%	-$5.53K	0.06%	243
2024 Q4	$409K	Buy	12,080 +1,481	+14%	+$53.3K	0.05%	272
2024 Q3	$365K	Buy	10,599 +487	+5%	+$19.9K	0.05%	296
2024 Q2	$389K	Buy	10,112 +52	+0.5%	+$2.19K	0.06%	262
2024 Q1	$449K	Sell	10,060 -6,925	-41%	-$286K	0.07%	246
2023 Q4	$630K	Buy	16,985 +3,094	+22%	+$111K	0.09%	248
2023 Q3	$504K	Buy	+13,891	New	+$493K	0.08%	273

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Continuum Advisory's GSK Position: Q2 2026 in Review

Continuum Advisory opened a new position in GSK (GSK) in Q2 2026: 5,000 shares worth $262K. The stake represents 0.02% of the portfolio and ranks #404 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in GSK as recently as Q3 2025.

Continuum Advisory first reported a position in GSK in Q3 2023 and has held it in 10 quarters since. The position peaked at $630K in Q4 2023. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Continuum Advisory held 5,000 shares of GSK worth $262K as of Q2 2026.
GSK was a new Continuum Advisory position in Q2 2026.
GSK made up 0.02% of Continuum Advisory's portfolio in Q2 2026, its #404 holding.
Continuum Advisory first reported a position in GSK in Q3 2023 and has held it in 10 quarters since.
Continuum Advisory's GSK position peaked at $630K in Q4 2023.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.